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ABSTRACT 26 
 27 
Blastocystis is the most common human enteric protist with controversial clinical 28 
significance. Metronidazole is considered first- line treatment for Blastocystis infection 29 
however there has been increasing evidence on the lack of efficacy of this treatment. 30 
Treatment failure has been reported in several clinical cases and recent in vitro studies have 31 
suggested the occurrence of metronidazole resistant strains. In this study we tested 12 32 
Blastocystis isolates from four common Blastocystis subtypes (ST1, ST3, ST4 and ST8) 33 
against 12 commonly used antimicrobials (metronidazole, paromomycin, ornidazole, 34 
albendazole, ivermectin, trimethoprim- sulfamethoxazole, furazolidone, nitazoxonide, 35 
secnidazole, fluconazole, nystatin and itraconazole) at 10 different concentrations in vitro. It 36 
was found that all subtypes showed little sensitivity to the commonly used metronidazole, 37 
paromomycin and triple therapy (furazolidone, nitazoxanide and secnidazole). This study 38 
highlights the efficacy of other potential drug treatments including trimethoprim- 39 
sulfamethoxazole and ivermectin and suggests that current treatment regimens be revised.  40 
 41 
INTRODUCTION 42 
 43 
Blastocystis is the most common enteric protist found in humans with rates of infection 44 
ranging from 2-100% in developed and developing countries (1, 2). There have been 17 45 
subtypes (ST) identified from humans and animals with ST1- 9 being identified in humans 46 
(3-5). ST3 is the predominant subtype found in most human studies (6-8). There have been 47 
numerous studies that have highlighted the clinical relevance of Blastocystis and an 48 
association between subtype and symptoms has been made (9-12). Although the pathogenic 49 
potential of this parasite has long been documented, there is still debate on whether 50 
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Blastocystis infections should be treated and therefore only a small number of studies have 51 
looked at treatment options for Blastocystis infection (13). Most case studies report first line 52 
treatment with metronidazole and have found varying rates of efficacy with ranges of 0% to 53 
100% (10, 14-16). Other antimicrobials which have been used to treat Blastocystis infection 54 
include iodoquinol, ketoconazole, nitazoxanide, paromomycin, tinidazole and trimethoprim- 55 
sulfamethoxazole all with varying results (17-21). There have only been four previous studies 56 
to look at in vitro susceptibility patterns of Blastocystis all of which have had a small number 57 
of study isolates. From these studies though, it is apparent that different subtypes show 58 
different susceptibility patterns and that metronidazole is not the most effective treatment for 59 
Blastocystis infection (22-25). In this study the in vitro susceptibility patterns of 12 different 60 
commonly used antiparasitics and antimicrobials (metronidazole, paromomycin, ornidazole, 61 
albendazole, ivermectin, trimethoprim- sulfamethoxazole, furazolidone, nitazoxonide, 62 
secnidazole, fluconazole, nystatin and itraconazole) were examined against 12 clinical 63 
isolates of Blastocystis from four different subtypes (ST1, ST3, ST4 and ST8) run in 64 
triplicate. These results show the lack of efficacy of the most common used drugs for 65 
antiparasitic treatment including metronidazole. This study shows other possible treatment 66 
options including trimethoprim- sulfamethoxazole and ivermectin.  67 
 68 
MATERIALS AND METHODS 69 
 70 
 Blastocystis cultures- twelve Blastocystis isolates from stool samples submitted to St. 71 
Vincent’s Hospital Microbiology Department were used for the study. All patients had a 72 
history of gastrointestinal symptoms including diarrhoea and cramps but had no previous 73 
treatment for Blastocystis. Samples were identified as positive for Blastocystis by microscopy 74 
of a permanent Iron Haematoxylin stain and confirmed by PCR using a previously published 75 
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method (26). For culture purposes 10mg of fresh sample was inoculated into a diphasic xenic 76 
dorset egg slope (Oxoid) using a previously published method (27). Xenic cultures were 77 
maintained by passaging every four days in the same media and incubated at 35˚C. 78 
Blastocystis subtyping- DNA was extracted from Blastocystis cultures using the 79 
Bioline Isolate fecal DNA kit as per manufacturer’s instructions, and were submitted to PCR 80 
for the detection of Blastocystis sp. using a previously described method (26). DNA sequence 81 
analysis was performed on all PCR products generated. PCR products were purified using 82 
SureClean Plus (Bioline) as per the manufacturer’s instructions and sent to the Australian 83 
Genome Research Facility (Westmead Millennium Institute, Sydney) for sequencing in both 84 
directions. Reads were assembled into a consensus. The SSU rDNA sequences were then 85 
compared to those available in the GenBank database using the BLASTN program run on the 86 
National Centre for Biotechnology Information server 87 
(http://www.ncbi.nlm.nih.gov/BLAST). 88 
Antimicrobial susceptibility testing- The following agents were used for 89 
susceptibility testing: metronidazole, paromomycin, ornidazole, albendazole, ivermectin, 90 
trimethoprim- sulfamethoxazole (TMP-SMX), furazolidone, nitazoxonide, secnidazole, 91 
fluconazole, nystatin and itraconazole. Metronidazole (Pfizer, NSW, Australia) in liquid form 92 
at 5mg/ml was used as a stock solution and diluted with phosphate-buffered saline (PBS) to 93 
cover a concentration range of 1000µg/ml to 1µg/ml by doubling dilution. Ornidazole 94 
(provided by J. Upcroft, Queensland Institute of Medical Research) in powder form was 95 
dissolved in 50% ethanol to 5mg/ml and diluted as above. Paromomycin sulphate, 96 
furazolidone, nitazoxanide, secnidazole (Sigma-Aldrich, Sydney, NSW, Australia) 97 
fluconazole (Diflucan, Pfizer, NSW, Australia) and itraconazole (Sporanox, Janssen 98 
Pharmaceuticals Inc, NSW, Australia) in powder form were suspended in 10% ethanol to 99 
make stock solutions of 5mg/ml and diluted in the same manner as above. Albendazole 100 
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tablets (GlaxoSmithKline, VIC, Australia) were dissolved in glacial acetic acid to 5mg/ml 101 
and diluted as above. Ivermectin tablets (Merck Sharp & Dohme Pty Ltd, NSW, Australia) 102 
were dissolved in methanol to 5mg/ml and diluted as above. TMP-SMX in liquid form was 103 
diluted to 40mg/ml sulfamethoxazole and 8mg/ml trimethoprim with PBS and then diluted as 104 
above. Nystatin (Omegapharm, VIC, Australia) in liquid form was diluted to 5mg/ml in PBS 105 
and diluted as above. 100µl of the respective antibiotic dilutions were inoculated in to 96 well 106 
microtitre plates and 100µl of Blastocystis culture was added to each dilution. A control 107 
containing 100µl of 10% ethanol was performed for all drugs in powder form to rule out any 108 
inhibitory effects of the solvent on Blastocystis. 100µl of PBS buffer was used for the 109 
metronidazole control, 100µl of diluted glacial acetic acid for the albendazole control and 110 
100µl of diluted methanol for the ivermectin control were used. All drug testing was 111 
performed in triplicate. Microtitre plates were then incubated in anaerobic conditions at 35˚C.  112 
Cell concentration and viability was determined quantitatively by the trypan blue dye 113 
exclusion method (28) by counting each dilution using Kova slides viewed under phase-114 
contrast microscopy and then counted every day for 4 days. As Blastocystis numbers in 115 
negative controls decline after 92 hours, susceptibility testing with each compound was only 116 
performed for 4 days. The minimal inhibitory concentration (MIC) was determined by the 117 
concentration of drug where there were lower numbers of growth compared to the control and 118 
the minimal lethal concentration (MLC) was determined to be the concentration at which no 119 
Blastocystis cells were observed. 120 
 Statistical anaylsis- Statistical analysis was performed in R version 3.1.0 with 121 
graphics constructed using the ggplot2 package, Poisson regression fitted using the glm 122 
function and likelihood ratio testing performed using the lmtest package. In the Poisson 123 
regression model, concentration is nested within condition. Confidence intervals in Figure(s) 124 
1- 4 (and supplementary file Fig. 5- 13) are obtained using bootstrapping. 125 
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Characterisation of bacteria present in xenic cultures- All samples were tested for 126 
enteric bacterial pathogens in the clinical laboratory prior to parasite culture. During parasite 127 
culture the bacterial flora present in each sample was characterised before antibiotic testing 128 
and at the end of the 4 days. Supernatant from each Blastocystis culture was inoculated onto 129 
the following bacteriological media: Brilliance UTI agar, MacConkey agar and anaerobic 130 
agar (Thermofisher Scientific Australia Pty Ltd., VIC, Australia). Aerobic plates were 131 
incubated in CO2 at 35˚C for 24 to 48h while the anaerobic plates were incubated for 48h 132 
under anaerobic conditions using an Anoxomat Mark II system (Mart Microbiology) with the 133 
following gas composition: 0.16% O2, 5% H2, 10% CO2, and 85% N2. All bacteria grown on 134 
agar plates were identified to species level using routine bacteriological procedures including 135 
biochemical testing and identification using the Bruker microflex MALDI-TOF.  136 
 137 
RESULTS 138 
 139 
 Blastocystis subtyping- there were four subtypes identified by sequencing and 140 
BLAST searching- five ST1, four ST3, two ST4 and one ST8.  141 
 Antimicrobial testing- There was a progressive reduction in the number of 142 
Blastocystis cells seen during the 4 days at all concentrations which were comparable to the 143 
control. There was a variation seen between each isolate even within the subtypes. The MIC 144 
values for the compounds were- metronidazole 250 µg/ml- 64 µg/ml, ornidazole 125 µg/ml – 145 
32 µg/ml, secnidazole 64 µg/ml- 16 µg/ml, paromomycin 1 µg/ml, albendazole 64 µg/ml- 16 146 
µg/ml, furazolidone 250 µg/ml-  125 µg/ml, nitazoxanide 500 µg/ml- 250 µg/ml, fluconazole 147 
500 µg/ml- 250 µg/ml, itraconazole 500 µg/ml- 250 µg/ml and nystatin 250 µg/ml. Due to 148 
time and space constraints and the obvious lack of efficacy after the 2nd concentration, the 149 
anti-fungals were only tested over 3 days for four different concentrations.  Ivermectin had an 150 
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MLC of 64 µg/ml- 32 µg/ml, and TMP-SMX had an MLC of 100 µg/ml/500 µg/ml- 12 151 
µg/ml/ 64 µg/ml. TMP-SMX and ivermectin were the only drugs where there was no growth 152 
at the two highest concentrations for all the isolates. Secnidazole was the only other drug 153 
which had no growth at the highest concentration for most of the isolates. Paramomycin was 154 
the only drug observed where the lower concentrations did not outgrow the control. Fig. 1-4 155 
show the cell counts vs concentration of drug for day 1 for metronidazole, paromomycin, 156 
trimethroprim- sulphamethoxazole and ivermectin. Due to the large amount of data received 157 
from this study, all other results are presented in a supplementary file.  158 
 Subtype dependency- slight differences were noted between subtypes and response 159 
to drug concentration as stated below.  160 
 Statistical analysis- In Fig. 1- 4 (and the supplementary files Fig. 5-13) the mean 161 
number of counts is indicated by a symbol and the lines represent confidence intervals for the 162 
mean cell counts. We observe that there are large differences in the reaction to the different 163 
concentrations of each agent between the subtypes. For example, TMP-SMX is more 164 
effective for ST3 than the other subtypes at lower concentrations, but Albendazole is more 165 
effective for ST1 and ST4 than ST3. For most agents the cell counts after one day are very 166 
low for high concentrations of the agent, and differences between subtypes cease to exist. 167 
This interaction between agent, concentration and subtype on cell count is confirmed using a 168 
generalised linear model, with the three-way interaction between these variables identified as 169 
statistically significant (p-value<0.0001). 170 
Bacteria present in cultures- There were no enteric bacterial pathogens identified 171 
from clinical laboratory testing. The bacteria isolated from the cultures were as follows- 172 
Escherichia coli, Enterococcus faecalis, Clostridium butyricium, Provotella sp and 173 
Citrobacter freundii. There did not appear to be any effect on the bacteria present in the 174 
cultures before and after treatment and within the subtypes from the bacteria that were 175 
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identified from culturing. It is likely that there are numerous amounts of gut bacteria that we 176 
were unable to identify through routine microbiological testing and only 16s rRNA testing 177 
would be able to confirm conclusively if there was a change in the bacteria before and after 178 
antibiotic treatment. 179 
  180 
DISCUSSION 181 
Blastocystis is the most common enteric protist found in humans. Though there is still 182 
some discussion about the pathogenicity of Blastocystis, treatment failure has been widely 183 
reported in the literature (29). This study suggests that though metronidazole is the most 184 
common drug therapy used for Blastocystis treatment, this should be reconsidered as other 185 
options such as TMP-SMX or ivermectin are much more effective as an antiparasitic agent as 186 
shown in this study.  187 
Metronidazole was found to have an inhibitory effect only up to the third highest 188 
concentration tested of 125µg/ml as shown in Fig. 1. Metronidazole is the most frequently 189 
prescribed antibiotic for Blastocystis treatment with high rates of clearance being reported 190 
from some clinical studies (15, 30, 31). Metronidazole resistance in Blastocystis has been 191 
reported since 1996 (32) and it was suggested that this could be ST dependent. Our study 192 
does not show that one ST is more resistant than others to metronidazole. In this study it was 193 
observed that there were much higher cell numbers seen in treated cultures with a 194 
concentration of 64µg/ml to the lowest concentration of 1µg/ml compared to the control 195 
except for ST8. One study suggested that there is a mechanism involved in Blastocystis that 196 
produces higher numbers of viable cells by regulating the apoptotic process in response to 197 
treatment with metronidazole which is what was probably witnessed in our study (25). This 198 
indicates that if metronidazole is to be used, it should be used at the highest concentration 199 
possible. This is not ideal though with many possible side effects being related to 200 
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metronidazole treatment such as nausea and vomiting. Also there was never a total clearance 201 
of Blastocystis noted at even the highest concentration suggesting that metronidazole does not 202 
have a complete effect on Blastocystis. It is clear that metronidazole should not be the drug of 203 
choice for the treatment of Blastocystis.  204 
Ornidazole was shown to be highly effective against other enteric protists including 205 
Dientamoeba fragilis (33). Blastocystis is commonly found in conjunction with D. fragilis in 206 
stool samples from patients and a drug therapy that cleared both parasites would be beneficial 207 
to patients. In this study ornidazole only had an inhibitory effect up to the third highest 208 
concentration at 125µg/ml. This indicates that ornidazole is not ideal for the treatment of 209 
Blastocystis. 210 
The prescription of a triple drug therapy is becoming common practice by some 211 
physicians (using secnidazole, furazolidone and nitazoxanide) (34). The premise behind a 212 
triple therapy is that the combination of three drugs will have the highest possible efficacy 213 
against the pathogen. In this study it was found that two of the three drugs used for triple 214 
therapy (furazolidone and nitazoxanide) had little to no effect at all on Blastocystis. The only 215 
drug that did have an effect was secnidazole with an efficacy noted up to a concentration of 216 
64µg/ml but then, like metronidazole, there was an increase in cell numbers compared to the 217 
control. Secnidazole is a nitroimidazole like metronidazole and ornidazole and therefore the 218 
same apoptotic effect may be expected to be seen. Secnidazole was shown to be effective for 219 
the treatment of D. fragilis infections (35) and this could be an option at the highest 220 
concentration for Blastocystis. Nitazoxanide was previously shown to have high clearance 221 
rates against Blastocystis in children with 97-100% efficacy reported (36). This drug has no 222 
serious side-effects suggesting it to be a good alternative option for treatment, however in this 223 
study it was shown that nitazoxanide had little effect on Blastocystis even at the highest 224 
concentration of 500µg/ml. Furazolidone had little effect at 250µg/ml and no effect after the 225 
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third highest concentration at 125µg/ml. It was previously stated that furazolidone has some 226 
activity against Blastocystis at 100µg/ml but our results do not agree with this (22). The use 227 
of a triple therapy using drugs that possess little anti-parasitic activity on Blastocystis is a 228 
practice not to be encouraged and can have serious consequences. An overload of antibiotics 229 
can have a detrimental effect on the patient causing sickness. Another consequence of the 230 
unnecessary use of drugs is the development of drug resistance within the microbial gut flora 231 
that may have other consequences for the patient.  232 
Paromomycin is currently one of the recommended treatment options by the Centre 233 
for Disease Control (CDC) and the Australian Therapeutic Guidelines for several enteric 234 
parasites including Blastocystis. There have been several case studies that have shown the 235 
effectiveness of paromomycin (19, 29, 37, 38). An in vitro study contradicts these by 236 
showing paromomycin to be completely ineffective (22). Our study agrees with Mirza et al 237 
(2011) in that paromomycin did not have a lethal effect even at the highest concentrations as 238 
shown in Fig. 2. Paromomycin was the only drug where the lower concentrations did not 239 
outgrow the control but there was also high numbers of cells seen even at the highest 240 
concentration. Paromomycin is a poorly absorbed aminoglycoside and from this study and 241 
the previous in vitro study it cannot be recommended as a suitable treatment. 242 
A recent review on antimicrobial treatments for Blastocystis suggested that TMP-243 
SMX is a good alternative to metronidazole with less side effects and being more cost 244 
effective (34). It states that it is not known if TMP-SMX has a direct effect on the 245 
Blastocystis or on the gut bacteria which is essential for Blastocystis survival. In this study we 246 
examined the bacteria present before and after treatment from these cultures and found that 247 
there was no difference in the bacteria present at the different concentrations which suggests 248 
that the death of Blastocystis was not due to the removal of the bacteria, but this is not 249 
conclusive as we were not able to identify all the bacteria that might be present in these 250 
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samples without thorough 16s rRNA testing which we were not able to complete. These 251 
results are just based on the bacteria that are able to be cultured by routine microbiology 252 
testing. TMP-SMX was seen to be highly effective up to a concentration of 253 
500µg/ml/100µg/ml and appears to be the most effective drug against all the STs. TMP-SMX 254 
was also the only drug studied that had no growth up to a concentration of 255 
500µg/ml/100µg/ml as shown in Fig. 3. TMP-SMX was shown to have high clearance rates 256 
in previous clinical studies (10, 39) and was also shown to have a high efficacy in a previous 257 
in vitro study (22). The weight of evidence indicates that TMP-SMX should be the first line 258 
treatment for Blastocystis infection due to it having a higher efficacy than metronidazole. It 259 
also has fewer side effects on patients.  260 
Ivermectin and albendazole are both commonly used anti-helminth treatments. 261 
Neither of these drugs has previously been tested in vitro against Blastocystis. In this study it 262 
was found that albendazole had a lethal concentration up to 250µg/ml and ivermetcin up to 263 
125µg/ml (Fig. 4) suggesting that taken in high doses these drugs are an option for treatment. 264 
In this study we tried to test a wide variety of drugs to see if any had an effect on 265 
killing Blastocystis. The three anti-fungal drugs used in this study (fluconazole, nystatin and 266 
itraconazole) had little to no effect after the highest concentration of 500µg/ml showing that 267 
these are not good options for Blastocystis treatment.   268 
In this study there was much variation seen for the different drugs even within each of 269 
the subtypes. Due to this being the largest in vitro study completed so far it is difficult to 270 
comment on whether this has been seen in other studies with usually only one or two isolates 271 
from each ST being studied. Variation in cell viability within a ST was shown however in 272 
one previous study (22). This variation illustrates how difficult it may be to comment on ST 273 
resistance and suggests that perhaps certain STs may not be resistant, but individual isolates 274 
within STs may be resistant and therefore each isolate should be treated differently. There 275 
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was a suggestion that some STs are more pathogenic than others and that some STs may be 276 
more resistant to drugs than others. One study showed that ST3 had the highest increase in 277 
cell numbers after treatment with metronidazole suggesting this ST is more pathogenic and 278 
resistant to treatment but that was not seen in this current study (25). Another study compared 279 
ST4 and ST7 and showed that ST7 was resistant to metronidazole and sensitive to emetine, 280 
while ST4 was sensitive to metronidazole and resistant to emetine (22). Another study 281 
showed the inability of both metronidazole and TMP-SMX to clear ST1, ST3, ST4 and ST6 282 
(40). In this study we noted that there is a slight variation in the efficacy of different 283 
antibiotics against STs as shown where TMP-SMX is more effective against ST3 and 284 
albendazole is more effective against ST1 and ST4 over the other STs. We also noted that 285 
there were minor differences even within each ST. From these results we cannot conclusively 286 
say that any one ST is more resistant than the others but there is a statistically significant 287 
interaction between ST, cell count and concentration of drug that may play a role in 288 
Blastocystis treatment failure but further studies are needed. Intra-subtype differences shown 289 
by the alleles present may also play a role in the different reactions to drugs. Unfortunately 290 
for this study we were unable to identify the different alleles in the isolates but this is 291 
something to consider for further testing. The website http://pubmlst.org/blastocystis/ is able 292 
to designate isolates in to STs and find alleles present for each ST.  293 
The draft genome from the NandII ST1 (unpublished) isolate and the full genome for 294 
ST7 (41) have been described. The information from these genomes may be useful for 295 
developing new drug therapies by identifying genes that may be involved in drug absorption 296 
pathways. There appears to be quite a lot of genetic differences between the ST1 and ST7 297 
genomes with a higher GC% content in ST1 but also ST1 has a substantially smaller genome 298 
than ST7 (16.4 Mb and 18.8Mb respectively). The difference in genomes may mean that a 299 
drug that may work in one ST may not have any effect on another ST. The more information 300 
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gathered from the genomes of the different STs will be highly beneficial for the identification 301 
of possible drug therapies. Unfortunately as only these two genomes are currently available, 302 
and that ST7 is rarely seen in humans, only the information gathered from ST1 will be 303 
helpful at this time. Axenic cultures are preferred for genome sequencing but it is extremely 304 
difficult to axenise Blastocystis cultures. One study has shown the role mitochondrion like 305 
organelles play in the reduction of ferrodoxins in ST7 in the conversion of metronidazole into 306 
its active state. This knowledge about this particular metabolic pathway may help in the 307 
development of new drug therapies (42, 43). 308 
The development of a simple antimicrobial susceptibility testing system for 309 
Blastocystis would be highly beneficial for treatment. Until axenic culture of Blastocystis 310 
becomes easier, this may not be possible. 311 
 312 
CONCLUSION 313 
This study shows that metronidazole should not be used as first line treatment for 314 
Blastocystis infections due to its lack of efficacy in vitro and its ability to promote cell growth 315 
at lower drug concentrations. This study also highlights the lack of efficacy against 316 
Blastocystis of most commonly used antiprotozoal treatments and shows that there is no 317 
significant difference between STs to treatment. From the results presented here and from 318 
previous studies, we recommend the use of TMP-SMX as first line treatment as it appears to 319 
be the most effective at promoting Blastocystis clearance.  320 
 321 
  322 
 323 
 324 
 325 
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 447 
Fig. 1 Blastocystis cell counts at different concentrations of Metronidazole on Day 1. Mean 448 
cell counts are indicated by a symbol and the lines represent confidence intervals for the 449 
mean cell counts for each of the different subtypes.  450 
 451 
 452 
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 453 
Fig. 2 Blastocystis cell counts at different concentrations of Paromomycin on Day 1. Mean 454 
cell counts are indicated by a symbol and the lines represent confidence intervals for the 455 
mean cell counts for each of the different subtypes.  456 
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 458 
 459 
 460 
 461 
 19
 462 
Fig. 3. Blastocystis cell counts at different concentrations of Trimethoprim- 463 
Sulfamethoxazole on Day 1. Mean cell counts are indicated by a symbol and the lines 464 
represent confidence intervals for the mean cell counts for each of the different subtypes.  465 
 466 
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467 
Fig. 4. Blastocystis cell counts at different concentrations of ivermectin on Day 1. Mean cell 468 
counts are indicated by a symbol and the lines represent confidence intervals for the mean 469 
cell counts for each of the different subtypes.  470 
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